Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1153 - 1160 of 12141 results

EPA Set to Designate PFAS as Hazardous Substances Next Month
February 20, 2024| News

Experts: Best Bet in $300M Osage Nation Wind Farm Dispute Is Negotiation
February 19, 2024| News

Commerce Department Launches Cross-Sector Consortium on AI Safety — AI: The Washington Report
February 16, 2024| Article| Viewpoint

Client Corner: Meet Co-founder & CEO of Axoft, Paul Le Floch
February 16, 2024| Podcast| Viewpoint

TikToker Drug Ads Spark Demands for FDA to Clarify Its Authority
February 16, 2024| News

Quality System Harmonization Is Here, But with Small Benefit to Device Industry
February 15, 2024| Blog| Viewpoint

Major Win for California Privacy Protection Agency: Enforcement of Regulations Can Begin Immediately
February 15, 2024| Blog| Viewpoint

USCIS Fee Increases May Have Unintended Consequences
February 15, 2024| News
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
